Intravenous Artesunate and Malaria (IVAS)
Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kassala, Sudan, 249
- Recruiting
- Kassala
-
Contact:
- Abzinab A Ali, MD
- Phone Number: 122 +249911259199
- Email: ishagadamm@yahoo.com
-
Principal Investigator:
- Tajeldien A Abdulla, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
severe P.falciparum malaria-
Exclusion Criteria:
mixed infection Pregnant women -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: artesunate
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
|
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
quinine infusion 80 mg/kg every 8 hours till the patient can take orally
|
|
ACTIVE_COMPARATOR: quinine
quinine infusion 80 mg/kg every 8 hours
|
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
quinine infusion 80 mg/kg every 8 hours till the patient can take orally
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
clearance of the parasite and fever
Time Frame: 3 days
|
To compare the parasite clearance time and fever clearance time between the two groups
|
3 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Neuromuscular Agents
- Antimalarials
- Anthelmintics
- Muscle Relaxants, Central
- Schistosomicides
- Antiplatyhelmintic Agents
- Artesunate
- Quinine
Other Study ID Numbers
Other Study ID Numbers
- artesunate and malaria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.